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Studies on the functional and structuralabnormalities that develop as a conse-
quence of cardiovascular risk factors have
primarily focused on the left ventricle. Less
attention has been paid to the right ventri-
cle, despite evidence showing its extensive
involvement.
Left-sided heart disease may be associated
with the development of pulmonary hyperten-
sion in patients with systemic hypertension
and ischemic heart disease; in these condi-
tions, pulmonary hypertension develops as
a consequence of impaired left ventricular
relaxation. The elevation in pulmonary capil-
lary pressure due to a chronic increase in
left-sided filling pressure leads to lung capil-
lary injury and right ventricular overload
and failure through a cascade of anatomical
and functional effects.1
The increase in blood pressure often asso-
ciated with metabolic syndrome or type 2
diabetes mellitus may alter cardiac struc-
ture and function. The impact of systemic
hemodynamic overload on the pulmonary
circulation and the right ventricle was
highlighted several years ago by Olivari
et al.2 Biventricular dysfunction was docu-
mented in a small group of hypertensive
patients with left ventricular hypertrophy or
strain. Systemic hypertension was associated
with elevated pulmonary artery pressure and
pulmonary arteriole resistance. Additionally,
coinciding with the development of ECG
signs of left ventricular strain, the performance
of both ventricles was shown to deterio-
rate. Since these studies, the involvement of
the left and right ventricles in hypertensive
patients has been a subject of great interest.3
Elevated systemic pressure is associated
with right ventricular thickening, and right
ventricular remodeling develops in parallel
with left ventricular remodeling, likely as a
result of ventricular interdependence. Increased
pulmonary afterload and the influence of
trophic factors targeting both ventricles may
impair the right ventricular filling rate, which
accompanies a similar phenomenon in the
left ventricle.
This process is at least partly indepen-
dent of the structural remodeling of both
ventricles. In fact, in addition to the hemo-
dynamic stimuli, non-hemodynamic factors
may favor the development of inflamma-
tion and fibrosis. An increase in sympathetic
tone, an impairment in the balance between
vasoconstrictors and vasodilators and an
increase in growth factors, such as aldosterone,
angiotensin II, insulin-like growth factors,
endothelin and proto-oncogenes, acting on
both sides of the circulation may contribute
to abnormal vasoconstriction of the pulmo-
nary circulation and alter cardiac function.
A role has been proposed for impaired insulin
sensitivity leading to increased pulmonary
resistance,4 and ventricular systolic and dia-
stolic dysfunction were observed in patients
with other phenotypes of the insulin resis-
tance syndrome, such as non-alcoholic fatty
liver disease.5 Recently, in the MESA study,
overweight and obesity were independently
associated with differences in right ventri-
cular morphology, as evaluated by magnetic
resonance, even after adjusting for the respec-
tive left ventricular measurements. Increased
right ventricular afterload, increased blood
volume, hormonal effects or direct obesity-
related myocardial effects could explain this
association.6 Diabetes seems to affect right
ventricular glucose metabolism and systolic
function similar to the left ventricular, which
could be due to ventricular interdependence
and the uniform effect of diabetes on the
heart.7
The study by Paneni et al.8 provides new
information regarding the involvement of
the systolic and diastolic function of both
ventricles and identifies the most important
determinants of biventricular dysfunction.
The authors analyzed the degree of both left
and ventricular dysfunction by a tissue Doppler
evaluation of the myocardial performance
index (MPI) in 345 hypertensive patients,
and found that there was a progressive impair-
ment in systolic and diastolic function para-
meters in the left and right ventricles of
patients with metabolic syndrome or diabetes
alone or both diabetes mellitus and metabolic
syndrome.
The MPI is a parameter that can be derived
from conventional measurements and by tissue
Doppler imaging (TDI) measurements, and is
conceptually attractive as a global measure
of cardiac function.9,10 The TDI-derived MPI
offers the advantage of recording systolic and
diastolic tissue velocity simultaneously in the
same cardiac cycle. TDI-derived MPI has been
shown to be more sensitive than conventional
Doppler in detecting preclinical abnormalities
in cardiac function, as confirmed by Paneni
et al., showing a weaker correlations between
conventional MPI and metabolic parameters
compared with a TDI-derived MPI.
The findings by Paneni et al.8 further
strengthen the conclusion that a TDI-
derived MPI is reproducible and may allow
for a better estimation of preclinical abnor-
malities in cardiac function and a more
accurate prediction of cardiovascular risk.11,12
The authors were also able to define the
MPI ‘normal values’ according to the value
distribution in the large group of normal
subjects who were studied, whereas other
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studies have defined MPI cutoff values based
on prognostic significance, which has been
demonstrated in some but not all studies.
At first sight, the results of this study appear
to confirm previous findings that metabolic
syndrome and diabetes mellitus are associated
with increased left ventricular mass, a more
concentric geometry, diastolic filling abnor-
malities and a slightly reduced systolic fiber
shortening in the endocardium.13,14
However, these results are stimulating from
at least two perspectives. First, in this group
of patients, there is a significant influence of
metabolic abnormalities but not pressure load
on biventricular function. A possible explana-
tion is that most of the hypertensive patients
were receiving antihypertensive treatment and
had only slightly elevated BP values, which
might also explain the absence of elevated
filling pressures in the right and left ventricles,
as indicated by the E/E0 ratios. In addition,
this study measured the peripheral arterial
pressure, while differences in central blood
pressure might represent a stronger determi-
nant of myocardial hypertrophy and fibrosis.
The second interesting conclusion is the
effect of inflammation on cardiac function,
as indicated by the independent association
with plasma CRP (C-reactive protein). A pro-
inflammatory state is a common characteristic
of obesity, dyslipidemia, diabetes and meta-
bolic syndrome and has been associated with
left ventricular dysfunction and increased
risk of heart failure. Among the markers of
inflammation, CRP has been most exten-
sively studied, has been proven to be asso-
ciated with left ventricular hypertrophy (LVH)
and concentric remodeling and is an indepen-
dent predictor of heart failure. CRP could have
direct myocardial effects because CRP can
cause intimal hypertrophy both in vitro and
in animal studies or could act indirectly
by affecting perivascular fibrosis, leading to
functional diastolic and systolic abnormalities.
In this study, CRP was mostly increased in
patients with both diabetes and metabolic
syndrome, in whom LVH and relative wall
thickness were more severely increased and
functional abnormalities were more extensive.
Despite the above-mentioned results, the
study by Paneni et al.8 also has some
limitations, which the authors have partially
acknowledged. Estimating the glomerular
filtration rate would have added value to
the manuscript and could have provided
new data on the relationship between early
right ventricular dysfunction and changes in
kidney function.15–17
In conclusion, the study by Paneni et al.8
provides a valuable contribution to ongoing
research on the early impairment of cardiac
function on both sides in the presence of
cardiovascular risk factors.
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